Limits...
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.

Ito K, Semba T, Uenaka T, Wakabayashi T, Asada M, Funahashi Y - Cancer Sci. (2014)

Bottom Line: Treatment with E7820 (50 mg/kg) with erlotinib (60 mg/kg) showed a synergistic antitumor effect in three xenograft models.Immunohistochemical analysis indicated that combined treatment with E7820 and erlotinib significantly decreased microvessel density and increased apoptosis of tumor-associated endothelial cells compared with use of only one of the agents.This combination increased apoptosis in HUVECs through activation of both intrinsic and extrinsic apoptosis pathways in vitro.

View Article: PubMed Central - PubMed

Affiliation: Tsukuba Research Laboratory, Eisai Co., Ltd., Tsukuba, Japan.

Show MeSH

Related in: MedlinePlus

E7820 in combination with erlotinib enhanced antitumor activity. (a) In vivo antitumor activities of E7820 and/or erlotinib in non-small-cell lung cancer xenograft models (n = 6, per group). (b) Relative body weight (RBW). Experiment was carried out more than twice. *P < 0.05, compared with vehicle. **P < 0.05, compared with erlotinib and E7820.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317852&req=5

fig01: E7820 in combination with erlotinib enhanced antitumor activity. (a) In vivo antitumor activities of E7820 and/or erlotinib in non-small-cell lung cancer xenograft models (n = 6, per group). (b) Relative body weight (RBW). Experiment was carried out more than twice. *P < 0.05, compared with vehicle. **P < 0.05, compared with erlotinib and E7820.

Mentions: We investigated the in vivo antitumor activities of E7820, erlotinib, and E7820 in combination with erlotinib in nude mice bearing erlotinib-resistant NSCLC A549, H1975, or H1650 cells. Approximately 10 days after tumor transplantation, E7820 (25 or 50 mg/kg) and/or erlotinib (60 mg/kg) were given to the mice. The combination of E7820 at either dose with erlotinib showed a superior antitumor effect compared with E7820 or erlotinib alone in three xenograft models (Fig. 1a, Table 1; P < 0.05). The combination of E7820 at a dose of 50 mg/kg with erlotinib at a dose of 60 mg/kg was found to have a significantly synergistic antitumor effect in three xenograft models without severe body weight loss (P < 0.05; Fig. 1b, Table 1). These data show that the combination of E7820 with erlotinib is effective against NSCLC xenograft models resistant to EGFR-TKIs.


Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.

Ito K, Semba T, Uenaka T, Wakabayashi T, Asada M, Funahashi Y - Cancer Sci. (2014)

E7820 in combination with erlotinib enhanced antitumor activity. (a) In vivo antitumor activities of E7820 and/or erlotinib in non-small-cell lung cancer xenograft models (n = 6, per group). (b) Relative body weight (RBW). Experiment was carried out more than twice. *P < 0.05, compared with vehicle. **P < 0.05, compared with erlotinib and E7820.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317852&req=5

fig01: E7820 in combination with erlotinib enhanced antitumor activity. (a) In vivo antitumor activities of E7820 and/or erlotinib in non-small-cell lung cancer xenograft models (n = 6, per group). (b) Relative body weight (RBW). Experiment was carried out more than twice. *P < 0.05, compared with vehicle. **P < 0.05, compared with erlotinib and E7820.
Mentions: We investigated the in vivo antitumor activities of E7820, erlotinib, and E7820 in combination with erlotinib in nude mice bearing erlotinib-resistant NSCLC A549, H1975, or H1650 cells. Approximately 10 days after tumor transplantation, E7820 (25 or 50 mg/kg) and/or erlotinib (60 mg/kg) were given to the mice. The combination of E7820 at either dose with erlotinib showed a superior antitumor effect compared with E7820 or erlotinib alone in three xenograft models (Fig. 1a, Table 1; P < 0.05). The combination of E7820 at a dose of 50 mg/kg with erlotinib at a dose of 60 mg/kg was found to have a significantly synergistic antitumor effect in three xenograft models without severe body weight loss (P < 0.05; Fig. 1b, Table 1). These data show that the combination of E7820 with erlotinib is effective against NSCLC xenograft models resistant to EGFR-TKIs.

Bottom Line: Treatment with E7820 (50 mg/kg) with erlotinib (60 mg/kg) showed a synergistic antitumor effect in three xenograft models.Immunohistochemical analysis indicated that combined treatment with E7820 and erlotinib significantly decreased microvessel density and increased apoptosis of tumor-associated endothelial cells compared with use of only one of the agents.This combination increased apoptosis in HUVECs through activation of both intrinsic and extrinsic apoptosis pathways in vitro.

View Article: PubMed Central - PubMed

Affiliation: Tsukuba Research Laboratory, Eisai Co., Ltd., Tsukuba, Japan.

Show MeSH
Related in: MedlinePlus